Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 11/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445721 | 0.93 | USP2 (0.41) | HTR2CHTR2AHTR2BHTR6MAPT | |
| SCHEMBL6505821 | 0.93 | HTR6 (0.47) | HTR2CHTR2AHTR6MEN1KMT2A | |
| SCHEMBL3899180 | 0.87 | HRH3 (0.46) | — | |
| SCHEMBL3892958 | 0.87 | LMNA (0.44) | HTR2CHTR2AHTR2BHTR6DRD2 | |
| SCHEMBL5457597 | 0.86 | USP2 (0.40) | HTR2CHTR2AHTR6DRD2DRD3 | |
| SCHEMBL5455409 | 0.85 | HTR2A (0.41) | HTR2CHTR2ADRD2 | |
| SCHEMBL5457591 | 0.85 | RORC (0.36) | HTR2CHTR2AHTR6DRD2DRD3 | |
| SCHEMBL3900151 | 0.85 | ALDH1A1 (0.38) | HTR2CHTR2AHTR6MEN1KMT2A | |
| SCHEMBL5452671 | 0.84 | USP2 (0.34) | HTR2CHTR2AHTR6DRD2DRD3 | |
| SCHEMBL5466786 | 0.83 | SIGMAR1 (0.42) | HTR2CHTR2AHTR2BHTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| EP-1511727-B1 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20050261279-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| EP-1511727-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099786-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | SIGMAR1, CBR3, CBR1 | HTR2C 58/4885HTR2A 428/4885HTR2B 219/4885 |
| US-20050261279-A1 | Compounds | CBR1, CBR3, OXER1 | HTR2C 1249/4885HTR2A 3210/4885HTR2B 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.